We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Quantitative evaluation of hard exudates in diabetic macular edema after short-term intravitreal triamcinolone, dexamethasone implant or bevacizumab injections.
- Authors
Yong Un Shin; Eun Hee Hong; Han Woong Lim; Min Ho Kang; Mincheol Seong; Heeyoon Cho; Shin, Yong Un; Hong, Eun Hee; Lim, Han Woong; Kang, Min Ho; Seong, Mincheol; Cho, Heeyoon
- Abstract
<bold>Background: </bold>To quantitatively compare short-term hard exudates (HEs) alteration in patients with diabetic macular edema (DME) after intravitreal triamcinolone, dexamethasone implant or bevacizumab injections.<bold>Methods: </bold>This retrospective study enrolled DME eyes with HEs that underwent a single-dose intravitreal injection of triamcinolone (25 eyes), dexamethasone implant (20 eyes), or three monthly injections of bevacizumab (25 eyes) and completed at least three months of follow-up. All patients were examined before and after 1, 2 and 3 months of injections. Using color fundus photographs, the amount of HEs was quantified by two masked graders. The difference in HEs area between baseline and each follow-up visit was compared among the three groups.<bold>Results: </bold>After three months, HEs area was reduced to 52.9 ± 4.21% (P < 0.001) in the triamcinolone group, 63.6 ± 6.08% (P = 0.002) in the dexamethasone implant group, and 85.2 ± 5.07% (P = 0.198) in the bevacizumab group. A significant reduction in HEs appeared at one month in the triamcinolone group (53.5 ± 4.91%, P < 0.001) and at two months in the dexamethasone implant group (70.1 ± 5.21%, P = 0.039).<bold>Conclusions: </bold>Our study suggests intravitreal steroids (triamcinolone, dexamethasone implants) significantly reduce HEs in DME patients on short-term follow-up, whereas intravitreal bevacizumab does not. Therefore, intravitreal steroids may be useful in DME with HEs in the fovea.
- Subjects
CYCLOPENTAPHENANTHRENE; CARCINOGENS; BEVACIZUMAB; MEDICAL care; TRIAMCINOLONE; THERAPEUTIC use of glucocorticoids; NEOVASCULARIZATION inhibitors; VASCULAR endothelial growth factor antagonists; COMPARATIVE studies; CONTROLLED release drugs; DIABETIC retinopathy; EXUDATES &; transudates; INJECTIONS; RESEARCH methodology; MEDICAL cooperation; RESEARCH; RETINAL degeneration; VISUAL acuity; EVALUATION research; OPTICAL coherence tomography; RETROSPECTIVE studies; DEXAMETHASONE; DIAGNOSIS; THERAPEUTICS
- Publication
BMC Ophthalmology, 2017, Vol 17, p1
- ISSN
1471-2415
- Publication type
journal article
- DOI
10.1186/s12886-017-0578-0